Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is a dominant global player in the peptide synthesis market, holding its leading position due to a highly diversified product portfolio, strong international presence, and continuous strategic growth, often through agreements and acquisitions. The company provides a comprehensive suite of peptide synthesis products and services tailored for research, diagnostics, and therapeutics applications. Their offerings include essential reagents, instrumentation, and consumables that support various synthesis techniques, such as solid-phase peptide synthesis (SPPS) and solution-phase methods. Thermo Fisher’s widespread distribution network and robust customer support system solidify its role as a critical supplier for academic institutions, biotechnology companies, and pharmaceutical giants globally. By continually investing in research and development, Thermo Fisher ensures its technology remains at the forefront of the industry, enabling researchers to achieve reliable and scalable production of complex peptides crucial for drug discovery and biological studies.
Latest Market Research Report on Peptide Synthesis Download PDF Brochure Now
Merck KGaA
Merck KGaA is a foundational key player in the peptide synthesis market, leveraging its extensive expertise in life sciences and advanced chemical technologies to support both research and large-scale manufacturing. The company is perhaps best known in this domain for its Novabiochem product line, which provides a broad spectrum of high-quality reagents, resins, and specialized building blocks essential for efficient and reliable synthesis. Merck KGaA is deeply committed to innovation, actively supporting and supplying materials for advanced techniques, including microwave-assisted synthesis, which enhances reaction efficiency and significantly improves yield. The firm’s strong global footprint and strategic partnerships reinforce its competitive edge. By providing the critical chemical components required for developing new therapeutics, Merck KGaA plays a vital role in advancing biopharmaceutical R&D and maintaining the high standards necessary for complex peptide production worldwide.
GenScript
GenScript is a highly influential provider of custom peptide synthesis services, renowned globally for offering high-quality peptides with industry-leading speed, often delivering products in as fast as five days through its proprietary PepPower™ peptide synthesis platform. This proprietary microwave-assisted technology ensures rapid turnaround and guaranteed quantity for researchers across the world. GenScript’s capabilities span a vast range of complexity, including the synthesis of standard peptides, neoantigen peptides crucial for personalized cancer treatments, cyclic peptides, cosmetic peptides, and GLP-1 Receptor Agonists for metabolic disease research. Beyond synthesis, the company offers comprehensive quality control (QC) services under its AccuPep+ QC program, including solubility testing, TFA exchange to reduce acidic content, and endotoxin control and analysis. This commitment to speed, quality, and technical diversity, coupled with extensive peptide modification offerings, makes GenScript a go-to partner for accelerating diverse scientific research and drug development programs.
Bachem Holding AG
Bachem Holding AG, headquartered in Switzerland, stands as an industry powerhouse with over 50 years of specialized experience in peptide chemistry and research. The company focuses primarily on the process development and manufacturing of high-quality peptides for use as Active Pharmaceutical Ingredients (APIs) for the pharmaceutical and biotech industries. Bachem offers customized peptide services globally, covering the entire product lifecycle from preclinical and clinical stages through to large-scale commercial supply. It is known for integrating advanced synthesis methods, including both solid-phase and solution-phase synthesis. Bachem also employs innovative proprietary technologies, such as the Molecular Hiving technology licensed from JITSUBO, specifically for the production of cosmetic peptides. The company’s focus on stringent compliance, sustainability, and automated facilities ensures reliable, reproducible, and high-efficiency peptide production, solidifying its role as a leading global supplier.
AmbioPharm Inc.
AmbioPharm Inc. is recognized as a leader in large-scale peptide manufacturing, specializing in providing Current Good Manufacturing Practice (cGMP)-compliant peptide APIs necessary for late-stage clinical development and commercial supply. Operating with some of the largest peptide manufacturing capacities worldwide across facilities in the USA and China, AmbioPharm is strategically positioned to handle high-volume demands. The company supports projects from R&D through commercialization, using sophisticated methods including solid-phase, solution-phase, and hybrid synthesis techniques. AmbioPharm’s model emphasizes accelerating products from Phase II trials to market, backed by strong regulatory expertise and quality systems that meet global FDA inspection standards. In addition to APIs for pharmaceutical and biotech clients, they offer non-GMP services, vaccine components, and high-quality cosmetic peptides, making them a crucial partner for companies requiring scalable and compliant peptide production.
Biosynth Ltd.
Biosynth Ltd. has established itself as a complete one-stop-shop for peptides, built upon the unified expertise of several acquired global leaders in custom peptides, including vivitide, Pepscan, and Cambridge Research Biochemicals (CRB). The company offers comprehensive custom peptide synthesis services that range from small scale and simple sequences to the most difficult and complex projects, covering the entire product development lifecycle through commercial supply. Biosynth specializes in high-value areas such as neoantigen peptides for personalized cancer treatments and leverages unique proprietary technologies like Peptide CLIPS(TM) for discovering new highly constrained peptides with enhanced stability and affinity, suitable for diagnostic and therapeutic applications. Its strength lies in providing tailored solutions and deep scientific expertise, reducing the need for customers to manage multiple suppliers during drug discovery and development.
Asymchem
Asymchem is a premier global Contract Development and Manufacturing Organization (CDMO) and a market leader in peptide manufacturing, providing end-to-end services from early process development to commercial production. With a focus on innovation, quality, and efficiency, Asymchem supports complex peptide drug development projects, having completed numerous IND and Phase II/III peptide projects. The company utilizes a range of advanced synthesis technologies, including Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Native Chemical Ligation (NCL). Asymchem maintains seven state-of-the-art global production sites, boasting substantial SPPS capacity, which is critical for handling large-scale commercial needs, such as GLP-1 APIs. Their commitment to stringent GMP and FDA filing requirements ensures high quality control, making Asymchem a reliable partner for pharmaceutical companies seeking efficient, compliant, and scalable peptide supply.
CordenPharma
CordenPharma is a prominent German Contract Development and Manufacturing Organization (CDMO) known for offering comprehensive services across Active Pharmaceutical Ingredients (APIs), drug products, and pharma packaging. Within the peptide segment, CordenPharma provides a wide range of services, including the development and manufacturing of New Chemical Entities (NCEs) and peptide generics under cGMP conditions. The company utilizes various proprietary technology platforms designed for the effective development and manufacturing of complex peptides. CordenPharma has actively expanded its capabilities, focusing on early clinical peptide manufacturing to support projects that move quickly from IND-targeted peptide API stages through to injectable drug products. Its global infrastructure and commitment to quality make it a strategic partner for pharmaceutical and biotech companies needing integrated services throughout the drug development pipeline.
Lonza Group
Lonza Group is a globally recognized provider of specialized manufacturing and development services, positioned as a major player in the peptide synthesis market due to its substantial strategic investments and broad technological capabilities. Lonza specializes in providing customized solutions across the entire drug product lifecycle, from research to commercialization. Its peptide services are integrated into its larger biologics and small molecule offerings, leveraging innovation to meet the high standards required by the pharmaceutical industry. The company is globally acknowledged for its expertise and commitment to advancing the sector through technology development and highly compliant manufacturing practices, enabling biotech and pharmaceutical partners to accelerate the development of complex peptide therapeutics.
AAPPTec
AAPPTec, LLC is an American peptide synthesis company that offers a comprehensive suite of products and services, distinguishing itself by specializing in automated peptide synthesizers, peptide-related laboratory equipment, and high-quality reagents, alongside custom peptide synthesis. The company’s experienced peptide chemists are adept at efficiently preparing a vast array of sequences, including complex and long peptides, ensuring high purity levels. AAPPTec provides custom peptides and large custom peptide libraries at competitive prices, fulfilling requests from micrograms up to kilogram scale. By supplying both the necessary instruments for solid- and liquid-phase synthesis and the final high-quality peptides, AAPPTec supports organizations in streamlining their synthetic processes and achieving high-throughput, reliable results across various research and development applications.
CSBio
CSBio is a highly regarded manufacturer specializing in both custom peptides and advanced peptide synthesizers, catering to the needs of the pharmaceutical, biotech, and academic research communities. With over 30 years of experience, the company provides a wide range of services, encompassing the production of non-GMP to cGMP peptides and specialized peptide Active Pharmaceutical Ingredients (APIs). CSBio operates a state-of-the-art cGMP facility, allowing it to support both small-scale research demands and large-scale commercial production with consistent quality and high purity. Their selection of peptide synthesizers includes specialized models designed for high-purity and fully automated GMP pharmaceutical manufacturing, ensuring clients have the necessary tools and expertise to accelerate their peptide-related projects efficiently.
Latest Market Research Report on Peptide Synthesis Download PDF Brochure Now